ArticleJACC. Case reports2025
Iron Overload Cardiomyopathy in Myelodysplastic Syndrome: A Fatal Outcome After 20 Years of Chronic Transfusions.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIron overload cardiomyopathy (IOC) results from excess iron accumulation in the myocardium, usually because of genetic disorders or secondary hemochromatosis by multiple blood transfusions. CASE SUMMARY: A 42-year-old man with refractory heart failure was referred to our hospital. He had a history of myelodysplastic syndrome, requiring 112 U of blood transfusions over 16 years. Severe left ventricular dysfunction, elevated ferritin levels, and myocardial iron deposition confirmed by endomyocardial biopsy led to the diagnosis of IOC. Despite intensive management, the patient was discharged after death. DISCUSSION: Early IOC typically starts with asymptomatic diastolic dysfunction. Noninvasive modalities (eg, N-terminal pro-B-type natriuretic peptide, T2-star magnetic resonance imaging) are crucial for early detection. Iron chelation therapy may reverse cardiac dysfunction in the early phase but is less effective in advanced phases, highlighting the need for timely intervention. TAKE-HOME MESSAGE: Early detection, cardiac monitoring, and close collaboration between hematologists and cardiologists are essential to prevent IOC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.